Polynovo Limited · ASX:PNV
Polynovo — FY2023 Earnings Presentation
10 slides from Polynovo's earnings presentation, Aug 23, 2023
Slide 1: FY23 Results: Accelerating Global Impact
FY23 Results (in conjunction with Appendix 4E) Accelerating Global Impact 23 August 2023 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this pr
Slide 3: Next Generation Dermal Substitute
Next Generation Dermal Substitute NovoSorb BTM Publications 2023 61 153 2022 47 125 2021 37 71 2020 25 39 2019 16 26 2018 5 21 0 20 40 60 80 100 120 140 160 Abstracts Studies • Fully synthetic biodegradable polyurethane • On formulation • Full thickness burns and mixed- • Meningococcal septicaemia •
Slide 4: Growth
Growth Total Employees Customers (Hospitals) 218 638 152 470 355 106 78 249 47 60 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 Team expansion New applications ANZ U.S. UK/I Germany Canada Hong Kong India Spain France China Japan 4
Slide 5: Excited about the future
Excited about the future Uniquely situated to drive Global impact • Genius Technology for surgeons' simplicity and patient care • Surgeons engaged in unprompted trials and publications • New applications • Underserved market : From 800m to 7.2B people • Growing team size • Building a global footprin
Slide 6: FY23 Financial Results
& PolyNovo- FY23 Financial Results
Slide 7: Delivering on Revenue Growth
FY23 Financial Results Total Revenue ($m) 1.3 Delivering on Revenue Growth 5.7 0.5 3.8 • Total Revenue $66.5m up 58.8% 0.2 0.1 3.7 59.6 3.1 37.6 • Global NovoSorb sales $59.6m up 58.3% 1.0 25.5 4.0 19.1 9.3 FY19 FY20 FY21 FY22 FY23 • U.S. NovoSorb sales $46.1m up 44.6% (34.0% in local USD) NovoSorb
Slide 8: Capital Efficient whilst Driving Growth
FY23 Financial Results Capital Efficient whilst Driving Growth Revenue, Opex, NLAT ($m) (excl. non-cash items) • Operating Expenses – exc. Non-cash items and interest +48.9% • Investing capital raising funds to drive growth: – Geographic expansion - Entered Canada, Hong Kong and India 66.5 63.0 – Ne
Slide 9: FY23 Financial Results
FY23 Financial Results ($m) FY23 FY22 Change % Highlights Revenue (Excl. Interest) 65.7 41.9 56.8% Expenses Changes in inventories & WIP (4.4) (2.2) 101.3% • Total Revenue (incl. BARDA) +58.8% Employee-related expenses * (39.4) (21.4) 84.1% * R&D Costs (7.4) (5.7) 29.3% Corp, administrative & overhe
Slide 10: Slide 10